Harbin Pharmaceutical Group Co Ltd (SHSE:600664) Stock Price, Trades & News

Name	Current	Vs Industry
Cash-To-Debt	2.61
Equity-to-Asset	0.4
Debt-to-Equity	0.21
Debt-to-EBITDA	2.23
Interest Coverage	16.99
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.81	Distress Grey Safe
Beneish M-Score	-2.58	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	5
	3-Year EBITDA Growth Rate	-5.6
	3-Year EPS without NRI Growth Rate	10.1
	3-Year FCF Growth Rate	-18.4
	3-Year Book Growth Rate	9.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	19.38
	Future 3-5Y Total Revenue Growth Rate Estimate	3.11

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	57.18
	9-Day RSI	63.59
	14-Day RSI	66.41
	3-1 Month Momentum %	-12.15
	6-1 Month Momentum %	-9.66
	12-1 Month Momentum %	-19.08

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.45
	Quick Ratio	1.17
	Cash Ratio	0.42
	Days Inventory	61.4
	Days Sales Outstanding	106.79
	Days Payable	122.46

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.1
	Shareholder Yield %	3.62

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	25.32
	Operating Margin %	4.26
	Net Margin %	1.94
	EBITDA Margin %	3.43
	FCF Margin %	3.54
	OCF Margin %	4.5
	ROE %	5.46
	ROA %	2.18
	ROIC %	8.75
	3-Year ROIIC %	-1.99
	ROC (Joel Greenblatt) %	17.39
	ROCE %	8.01
	Years of Profitability over Past 10-Year	9

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	51.83
	Forward PE Ratio	34.56
	PE Ratio without NRI	41.19
	Shiller PE Ratio	51.83
	Price-to-Owner-Earnings	76.83
	PS Ratio	0.96
	PB Ratio	2.67
	Price-to-Tangible-Book	2.93
	Price-to-Free-Cash-Flow	30.82
	Price-to-Operating-Cash-Flow	24.02
	EV-to-EBIT	24.33
	EV-to-EBITDA	24.33
	EV-to-Revenue	0.83
	EV-to-FCF	23.54
	Price-to-GF-Value	1.77
	Price-to-Projected-FCF	2.57
	Price-to-Median-PS-Value	1.49
	Price-to-Graham-Number	2.32
	Price-to-Net-Current-Asset-Value	6.99
	Earnings Yield (Greenblatt) %	4.11
	FCF Yield %	3.61
	Forward Rate of Return (Yacktman) %	-26.42

Warning Signs

Warning! GuruFocus detected 6 Medium warning signs with 600664. Try a 7-Day Free Trial to check it out.

Harbin Pharmaceutical Group Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Harbin Pharmaceutical Group Co Ltd Stock Events

Financials Calendars

Event	Date	Price (¥)
1.3:1 Stock Split	2016-04-06	7.99 (+1.07%)
1.3:1 Stock Split	2011-08-01	9.97 (-1.46%)
1.3:1 Stock Split	2004-08-13	3.45 (-2.19%)
1.5:1 Stock Split	2003-07-17	7.01 (+1.54%)
1.2:1 Stock Split	2002-07-12	3.95 (+1.43%)
1.3:1 Stock Split	1997-04-24	2.77 (+0.56%)

Show

Entries

Press Release

	Subject	Date
No Press Release

Articles on Harbin Pharmaceutical Group Co Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.

Harbin Pharmaceutical Group Co Ltd - Class A

Business Description

Financial Strength